@inproceedings{inproceedings, title  = {{Abstract OT2-2-01: tnAcity: A phase II/III trial ofnab-paclitaxel (nab-P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC)}},

 publisher = {{American Association for Cancer Research}},

 url = {{}},

 year = {{2015}},

 month = {{5}},

 author = {{Yardley DA and Coleman RE and Conte P and O'Shaughnessy J and Cortes J and Glück S and Brufsky A and Nabholtz J-MA and Li L and Miller J and Barton D et al}},

 doi = {{10.1158/1538-7445.sabcs14-ot2-2-01}},

 journal = {{Ongoing Clinical Trials}},

 note = {{Accessed on 2025/10/10}}}